中华胰腺病杂志
中華胰腺病雜誌
중화이선병잡지
CHINESE JOURNAL OF PANCREATOLOGY
2015年
4期
229-232
,共4页
赵瑾%李兴德%孙广玉%周军%史英%李永生%高敬华
趙瑾%李興德%孫廣玉%週軍%史英%李永生%高敬華
조근%리흥덕%손엄옥%주군%사영%리영생%고경화
胰腺肿瘤%药物疗法%疗效比较研究%替吉奥%沙利度胺
胰腺腫瘤%藥物療法%療效比較研究%替吉奧%沙利度胺
이선종류%약물요법%료효비교연구%체길오%사리도알
Pancreatic neoplasms%Drug therapy%Comparative effectiveness research%S-1%Thalidomide
目的 观察替吉奥联合沙利度胺二线治疗晚期胰腺癌的临床疗效,探讨沙利度胺在胰腺癌治疗中的疗效和安全性.方法 收集2010年7月至2012年10月沧州市中心医院肿瘤内科收治的60例胰腺癌患者,采用随机、平行对照的方法分为单药组和联合组,分别给予单药替吉奥或替吉奥联合沙利度胺治疗,评价两组患者的疗效和不良反应.结果 单药组和联合组患者的疾病控制率分别为36.7％和46.7％,差异无统计学意义(P=0.31);两组无进展生存期分别为2.9个月和3.3个月,联合组显著长于单药组,差异有统计学意义(P＜0.05);联合组的Karnofsky评分、疼痛、睡眠和体重状况改善率分别为63.3％、46.7％、66.7％和53.3％,均显著优于单药组的30.0％、13.3％、30.0％和20.0％,差异有统计学意义(P值均＜0.05).两组患者化疗的不良反应主要为恶心、呕吐、疲劳和嗜睡,多为Ⅰ～Ⅱ度.结论 替吉奥联合沙利度胺二线治疗胰腺癌能够延长患者的无进展生存期,且安全性好,能提高患者生活质量.
目的 觀察替吉奧聯閤沙利度胺二線治療晚期胰腺癌的臨床療效,探討沙利度胺在胰腺癌治療中的療效和安全性.方法 收集2010年7月至2012年10月滄州市中心醫院腫瘤內科收治的60例胰腺癌患者,採用隨機、平行對照的方法分為單藥組和聯閤組,分彆給予單藥替吉奧或替吉奧聯閤沙利度胺治療,評價兩組患者的療效和不良反應.結果 單藥組和聯閤組患者的疾病控製率分彆為36.7％和46.7％,差異無統計學意義(P=0.31);兩組無進展生存期分彆為2.9箇月和3.3箇月,聯閤組顯著長于單藥組,差異有統計學意義(P＜0.05);聯閤組的Karnofsky評分、疼痛、睡眠和體重狀況改善率分彆為63.3％、46.7％、66.7％和53.3％,均顯著優于單藥組的30.0％、13.3％、30.0％和20.0％,差異有統計學意義(P值均＜0.05).兩組患者化療的不良反應主要為噁心、嘔吐、疲勞和嗜睡,多為Ⅰ～Ⅱ度.結論 替吉奧聯閤沙利度胺二線治療胰腺癌能夠延長患者的無進展生存期,且安全性好,能提高患者生活質量.
목적 관찰체길오연합사리도알이선치료만기이선암적림상료효,탐토사리도알재이선암치료중적료효화안전성.방법 수집2010년7월지2012년10월창주시중심의원종류내과수치적60례이선암환자,채용수궤、평행대조적방법분위단약조화연합조,분별급여단약체길오혹체길오연합사리도알치료,평개량조환자적료효화불량반응.결과 단약조화연합조환자적질병공제솔분별위36.7％화46.7％,차이무통계학의의(P=0.31);량조무진전생존기분별위2.9개월화3.3개월,연합조현저장우단약조,차이유통계학의의(P＜0.05);연합조적Karnofsky평분、동통、수면화체중상황개선솔분별위63.3％、46.7％、66.7％화53.3％,균현저우우단약조적30.0％、13.3％、30.0％화20.0％,차이유통계학의의(P치균＜0.05).량조환자화료적불량반응주요위악심、구토、피로화기수,다위Ⅰ～Ⅱ도.결론 체길오연합사리도알이선치료이선암능구연장환자적무진전생존기,차안전성호,능제고환자생활질량.
Objective To investigates the efficacy and tolerability of second line treatment with S-1 plus thalidomide in patients with advanced pancreatic cancer.Methods Sixty patients hospitalized in Department of Oncology of Cangzhou Central Hospital from July 2010 to October 2012 were included in this study.All the patients were diagnosed as having pancreatic carcinoma.The patients were randomly divided into two groups,one group was treated with S-1 alone,and the other group was treated with S-1 plus thalidomide.Then the efficacy and toxicity of two groups was evaluated.Results The disease control rates were 36.7％ and 46.7％ in the S-1 alone group and the S-1 plus thalidomide group,and the difference between the two groups was not statistically significant (P =0.31).The progression free survival (PFS) was 2.9 months and 3.3 months,and the difference between the two groups was statistically significant (P ＜ 0.05),the Karnofsky score,pain,sleep and weight improvement rate was 63.3％,46.7％,66.7％ and 53.3％ in combination group,which were significantly better than those in control group (30.0％,13.3％,30.0％ and 20.0％),and the difference between the two groups was statistically significant (P ＜ 0.05).The major adverse events were nausea,vomiting,fatigue and drowsiness,mainly of grades Ⅰ ～ Ⅱ.Conclusions S-1 plus thalidomide as second line treatment of pancreatic cancer can prolong the PSF of patients with advanced pancreatic cancer with excellent safety,and patients' quality of life is also improved.
